DrugDashboards

Famotidine

Famotidine · FAMOTIDINE 40 mg/5mL · For Suspension · Oral · Lupin Pharmaceuticals,Inc.

NDC 43386-0500-11 · 50 mL in 1 BOTTLE · ANDA · View full market →

The short version

Just 3 companies supply this market — thin enough that a single exit would be felt immediately. The price has held steady around $0.9875 per unit over the past year.

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

One drug, every price

The same NDC has different prices depending on who is paying. Units differ between rungs — compare within a rung over time, not rung against rung, unless the units match.

ⓘ How this was built
Data sources
  • CMS NADAC (pharmacy acquisition, weekly)
  • CMS Part B ASP quarterly payment limits
  • CMS Maximum Fair Prices (IRA negotiated, NDC-level)
  • Medicare Part D Spending by Drug (data.cms.gov, name-matched)
  • VA FSS / Big4 federal contract prices (va.gov, twice monthly)
  • ACA Federal Upper Limits + weighted AMP (data.medicaid.gov, monthly)
  • California SB-17 WAC filings (list price, per package)
Method

Each rung is the newest figure for this NDC from one federal price system, shown with its own unit. Part D is matched by drug name because CMS publishes no NDCs there; it is gross spending, before confidential rebates.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

  • Part D plans paid (avg)$0.1614per dosage unitgross, before rebates — matched by drug name · 2024
  • Medicaid generic ceiling (FUL)$0.9875per MLweighted avg manufacturer price $0.2993 · May 1, 2016

Medicare Part D

No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.

How Part D pricing works →

NADAC price per unit

$0$0.5$1.00$1.50Nov 2013May 2016$0.9875
31 price points · per · last surveyed Invalid Date · dashed = manufacturer avg (WAMP)Source: CMS NADAC

Supply fragility

Not scored — fragility is computed for NADAC-priced NDCs.

90-day shortage risk (model v2)

0.1%chance of a new FDA shortage posting for famotidine (other) in the next 90 days

sole-source market

For scale: the typical drug’s chance is about 0.1% — this one is in ordinary territory.

Backtested statistical model over the whole market, not this package alone. Model details →

Where it's made

Establishments this product's FDA label declares, located via FDA registration data. How we built this →

Regulatory

Application
ANDA201695
TE code
AB
Approval date
Dec 17, 2012
Patents / exclusivity
None on file

Shortage history

No FDA shortage reports for this drug or its presentations.

Recalls (this NDC)

  • Class III · TerminatedJun 20, 2014
    Novel Laboratories, Inc. — Failed Impurity/Degradation Specification; 12-month stability time point

Manufacturers of Famotidine (For Suspension)

LabelerStrengthFirst seenLast seen
Ajanta Pharma USA Inc.FAMOTIDINE 40 mg/5mLJul 15, 2026Sep 2, 2026
Dr. Reddy's Laboratories IncFAMOTIDINE 40 mg/5mLJul 15, 2026Sep 2, 2026
Lupin Pharmaceuticals,Inc.FAMOTIDINE 40 mg/5mLJul 15, 2026Sep 2, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Famotidine — NDC 43386-0500-11," retrieved September 3, 2026, https://drugdashboards.com/drug/43386050011.

Free to cite with attribution — see how the data is put together.